Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.95
NVAX's Cash-to-Debt is ranked lower than
81% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NVAX: 0.95 )
Ranked among companies with meaningful Cash-to-Debt only.
NVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 11.65 Max: No Debt
Current: 0.95
Equity-to-Asset 0.11
NVAX's Equity-to-Asset is ranked lower than
90% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVAX: 0.11 )
Ranked among companies with meaningful Equity-to-Asset only.
NVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.77 Max: 0.98
Current: 0.11
0.11
0.98
Piotroski F-Score: 1
Altman Z-Score: -3.40
Beneish M-Score: -8.48
WACC vs ROIC
18.75%
-442.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -1859.75
NVAX's Operating Margin % is ranked lower than
82% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NVAX: -1859.75 )
Ranked among companies with meaningful Operating Margin % only.
NVAX' s Operating Margin % Range Over the Past 10 Years
Min: -11502.46  Med: -824.36 Max: -134.38
Current: -1859.75
-11502.46
-134.38
Net Margin % -1908.41
NVAX's Net Margin % is ranked lower than
83% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NVAX: -1908.41 )
Ranked among companies with meaningful Net Margin % only.
NVAX' s Net Margin % Range Over the Past 10 Years
Min: -12414.15  Med: -880.1 Max: -129.13
Current: -1908.41
-12414.15
-129.13
ROE % -150.08
NVAX's ROE % is ranked lower than
87% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. NVAX: -150.08 )
Ranked among companies with meaningful ROE % only.
NVAX' s ROE % Range Over the Past 10 Years
Min: -150.08  Med: -43.4 Max: -32.12
Current: -150.08
-150.08
-32.12
ROA % -63.70
NVAX's ROA % is ranked lower than
74% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NVAX: -63.70 )
Ranked among companies with meaningful ROA % only.
NVAX' s ROA % Range Over the Past 10 Years
Min: -63.7  Med: -33.19 Max: -22.37
Current: -63.7
-63.7
-22.37
ROC (Joel Greenblatt) % -816.16
NVAX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NVAX: -816.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -816.16  Med: -427.33 Max: -182.47
Current: -816.16
-816.16
-182.47
3-Year Revenue Growth Rate -6.30
NVAX's 3-Year Revenue Growth Rate is ranked lower than
63% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NVAX: -6.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -57.7  Med: 1.8 Max: 247.6
Current: -6.3
-57.7
247.6
3-Year EBITDA Growth Rate 41.30
NVAX's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NVAX: 41.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -58.7  Med: -6 Max: 102.6
Current: 41.3
-58.7
102.6
3-Year EPS without NRI Growth Rate 39.70
NVAX's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NVAX: 39.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.2 Max: 52.3
Current: 39.7
0
52.3
GuruFocus has detected 4 Warning Signs with Novavax Inc $NVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVAX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVAX Guru Trades in Q1 2016

George Soros 30,300 sh (New)
Steven Cohen Sold Out
» More
Q2 2016

NVAX Guru Trades in Q2 2016

Steven Cohen 180,000 sh (unchged)
George Soros Sold Out
» More
Q3 2016

NVAX Guru Trades in Q3 2016

Paul Tudor Jones 115,000 sh (New)
Chuck Royce 900,000 sh (New)
» More
Q4 2016

NVAX Guru Trades in Q4 2016

Jim Simons 431,415 sh (New)
Chuck Royce 550,000 sh (-38.89%)
Paul Tudor Jones 40,944 sh (-64.40%)
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:PTI, NAS:MACK, NAS:AVDL, OTCPK:MEOBF, NAS:CARA, NAS:TLGT, NAS:NSTG, NAS:MYOK, NAS:RXDX, NAS:CLDX, NAS:AKBA, NAS:XBIT, NAS:TRVN, OTCPK:ABVC, NAS:CRBP, NAS:AGEN, NAS:MRUS, NAS:NK, NAS:CTMX, NAS:MCRB » details
Traded in other countries:NVV.Germany,
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax Inc was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company manages its business as one operating segment: developing recombinant vaccines. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc., Protein Sciences Corporation. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.

Ratios

vs
industry
vs
history
PB Ratio 7.49
NVAX's PB Ratio is ranked lower than
80% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. NVAX: 7.49 )
Ranked among companies with meaningful PB Ratio only.
NVAX' s PB Ratio Range Over the Past 10 Years
Min: 1.02  Med: 3.86 Max: 42.34
Current: 7.49
1.02
42.34
PS Ratio 23.38
NVAX's PS Ratio is ranked lower than
64% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. NVAX: 23.38 )
Ranked among companies with meaningful PS Ratio only.
NVAX' s PS Ratio Range Over the Past 10 Years
Min: 6.47  Med: 59.75 Max: 1903.33
Current: 23.38
6.47
1903.33
Current Ratio 4.68
NVAX's Current Ratio is ranked higher than
54% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NVAX: 4.68 )
Ranked among companies with meaningful Current Ratio only.
NVAX' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.42 Max: 37
Current: 4.68
0.44
37
Quick Ratio 4.68
NVAX's Quick Ratio is ranked higher than
55% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. NVAX: 4.68 )
Ranked among companies with meaningful Quick Ratio only.
NVAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.37 Max: 37
Current: 4.68
0.44
37
Days Sales Outstanding 13.65
NVAX's Days Sales Outstanding is ranked higher than
83% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. NVAX: 13.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.65  Med: 73.44 Max: 289.75
Current: 13.65
13.65
289.75

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 7.00
NVAX's 5-Year Yield-on-Cost % is ranked higher than
85% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. NVAX: 7.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 7
3-Year Average Share Buyback Ratio -22.20
NVAX's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. NVAX: -22.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.9  Med: -19.3 Max: -8.1
Current: -22.2
-29.9
-8.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.39
NVAX's Price-to-Median-PS-Value is ranked higher than
84% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NVAX: 0.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.94 Max: 22
Current: 0.39
0.07
22
Earnings Yield (Greenblatt) % -74.70
NVAX's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. NVAX: -74.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -169.5  Med: 0 Max: 0
Current: -74.7
-169.5
0

More Statistics

Revenue (TTM) (Mil) $15.81
EPS (TTM) $ -1.12
Beta2.17
Short Percentage of Float28.18%
52-Week Range $1.16 - 8.49
Shares Outstanding (Mil)271.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 42
EPS ($) -1.05 -0.64 -0.71 -0.59
EPS without NRI ($) -1.05 -0.64 -0.71 -0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on... Feb 20 2017
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on... Feb 20 2017
Biotech Industry Poised for a Breakout in 2017? Today's Reports on Evoke Pharma and Novavax Feb 16 2017
Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : February 14, 2017 Feb 14 2017
Cluster of Insider Buying at Clinical-Stage Vaccine Company, Massive Insider Selling at Analog Chip... Feb 03 2017
Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : January 27, 2017 Jan 27 2017
Novavax starts new clinical trial in bid to prove failed RSV vaccine Jan 19 2017
Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults Jan 19 2017
Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults Jan 19 2017
In Honor Of Friday The 13th, Here Are Some Of The Unluckiest Trades Of 2016 Jan 13 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
Novavax, Inc. – Value Analysis (NASDAQ:NVAX) : January 10, 2017 Jan 10 2017
Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : January 9, 2017 Jan 09 2017
5 Stocks Setting Up for Big Breakouts Jan 06 2017
Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 05 2017
Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)